azasetron has been researched along with Liver Neoplasms in 2 studies
azasetron: a selective 5-HT3 receptor antagonist; structure given in first source;
Liver Neoplasms: Tumors or cancer of the LIVER.
Excerpt | Relevance | Reference |
---|---|---|
"We performed a clinical evaluation on the antiemetic profile and the plasma concentration of Azasetron Hydrochloride (a new selective 5-HT3 receptor antagonist), in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma." | 9.08 | [Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma]. ( Beppu, T; Doi, K; Egami, H; Kudo, S; Kuramoto, M; Masuda, Y; Matsuda, T; Ogawa, M; Ohara, C; Yamanaka, T, 1998) |
"We performed a clinical evaluation on the antiemetic profile and the plasma concentration of Azasetron Hydrochloride (a new selective 5-HT3 receptor antagonist), in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma." | 5.08 | [Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma]. ( Beppu, T; Doi, K; Egami, H; Kudo, S; Kuramoto, M; Masuda, Y; Matsuda, T; Ogawa, M; Ohara, C; Yamanaka, T, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hashizume, J | 1 |
Higuchi, N | 1 |
Sato, K | 1 |
Kodama, Y | 1 |
Matsunaga, N | 1 |
Sakamoto, T | 1 |
Yamaguchi, K | 1 |
Nakamura, T | 1 |
Kitahara, T | 1 |
Sasaki, H | 1 |
Beppu, T | 1 |
Ogawa, M | 1 |
Yamanaka, T | 1 |
Egami, H | 1 |
Ohara, C | 1 |
Masuda, Y | 1 |
Kudo, S | 1 |
Kuramoto, M | 1 |
Doi, K | 1 |
Matsuda, T | 1 |
1 trial available for azasetron and Liver Neoplasms
Article | Year |
---|---|
[Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma].
Topics: Aged; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepato | 1998 |
1 other study available for azasetron and Liver Neoplasms
Article | Year |
---|---|
Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bridged Bicyclo Comp | 2016 |